By Prof. Paolo Gontero (Turin, IT) On 17-18 May, Turin hosted a successful second edition of BCa19 in the Lingotto Congress Centre, a structure designed by Renzo Piano as a refashioning of an old FIAT building. Two hundred and eighty...

While progress in bladder cancer treatment has lagged behind other cancers in previous decades, the EAU’s BCa19 meeting comes at a time when experts are seeing the emergence of a lot of new developments, according to Prof. Peter Black...

Radical cystectomy is the standard for muscle-invasive bladder cancer and with mostly elderly men as patients, doctors are seeking ways to improved recovery regimes following radical surgeries. “64% of patients have one or more complications, 13% have a major...

There are increment developments in genomics research on bladder cancer (BCa) molecular classification, but drug development and their prospective benefits still remain unclear due to the complex types of aggressive disease and the lack of sufficient patient numbers in...

There is a lot of work that needs to be done to address gaps in the guidelines for managing muscle-invasive bladder cancer (MIBC), but at the same time, there are new prospects in biological predictors that could transform the...

Refining current guidelines to reflect the evolving treatment strategies in non-muscle invasive bladder cancer (NMIBC) and the need for a more collaborative and responsive multidisciplinary teamwork were among the main topics examined at the first plenary session of the...

Bladder cancer, one of the most aggressive recurrent onco-urological malignancies, poses a special challenge to cancer experts due to the lack of response from many patients particularly  those who are diagnosed at a late stage. The EAU Update on...

Recent gains in precisely identifying bladder cancer variants and their respective classification can go a long way in enabling physicians to determine the proper treatment, which leads to better or timely therapies for many bladder cancer patients. Bladder cancer...